Global Lateral Flow Assays Market to Reach USD 13.85 Billion by 2027 Due to Benefits of Rapid Tests and Growing Demand for POC Testing
By LabMedica International staff writers Posted on 20 May 2021 |

Illustration
The global lateral flow assays market is expected to grow at a CAGR of 8.8% from 2020 to 2027 to reach USD 13.85 billion by 2027, driven mainly by the benefits of LFA-based rapid tests over laboratory testing and growing demand for point-of-care testing.
These are the latest findings of Meticulous Research (Redding, CA, USA), a market intelligence provider.
Lateral flow assays are devices used to confirm the presence or absence of a target analyte without the need for lab equipment. These devices are widely used in hospitals and clinical laboratories for the qualitative and quantitative detection of specific antigens and antibodies. It is a simple and low-cost technology used in qualitative and quantitative detection of pathogens or biomarkers in humans or animals, or contaminants or toxic elements in water supplies, foodstuffs, or animal feeds.
The growth of the overall lateral flow assays market is mainly attributed to the benefits of LFA-based rapid tests over laboratory testing, increasing usage of home-based lateral flow assay kits, growing demand for point-of-care testing, increasing prevalence of chronic & infectious diseases, and growing acceptance of smart devices. In addition, evolving applications of lateral flow assays and rising demand for lateral flow assays in the food & beverage industry offer significant growth opportunities for players operating in the lateral flow assays market. On the other hand, the reluctance towards changing existing diagnostic practices and the development of multiplexing assays are some of the factors challenging the growth of this market to a certain extent. Also, variance in lateral flow assay test results and stringent regulations are expected to hinder the growth of this market.
Based on product, the kits & reagents segment accounted for the largest share of the overall lateral flow assays market in 2020, led by the higher adoption rate of kits & reagents, increasing use of home-based lateral flow assay devices, and growing demand for point-of-care testing. On the basis of technique, the sandwich assays segment accounted for the largest share of the overall lateral flow assays market in 2020, due to the wide application of sandwich assays in various medical testing settings and their advantages, such as higher sensitivity and specificity for larger analytes.
Based on application, the clinical testing segment accounted for the largest share of the overall lateral flow assays market in 2020, on the back of increasing healthcare expenditure, rising initiatives towards health awareness, growing awareness about clinical testing, and increasing spread of various chronic and infectious diseases. Based on end user, diagnostic laboratories accounted for the largest share of the overall lateral flow assays market in 2020, on account of increasing adoption of lateral flow assays due to their benefits over conventional laboratory tests, increasing use of PoC tests, growing hospital admissions, and rapid growth in demand for lateral flow tests during COVID-19. Geographically, North America accounted for the largest share of the global lateral flow assays market in 2020, followed by Europe and Asia-Pacific. The increasing prevalence of chronic and infectious diseases, rising geriatric population, growing demand for point-of-care testing facilities, and presence of key players in the region are driving the growth of the North American lateral flow assays market.
Related Links:
Meticulous Research
These are the latest findings of Meticulous Research (Redding, CA, USA), a market intelligence provider.
Lateral flow assays are devices used to confirm the presence or absence of a target analyte without the need for lab equipment. These devices are widely used in hospitals and clinical laboratories for the qualitative and quantitative detection of specific antigens and antibodies. It is a simple and low-cost technology used in qualitative and quantitative detection of pathogens or biomarkers in humans or animals, or contaminants or toxic elements in water supplies, foodstuffs, or animal feeds.
The growth of the overall lateral flow assays market is mainly attributed to the benefits of LFA-based rapid tests over laboratory testing, increasing usage of home-based lateral flow assay kits, growing demand for point-of-care testing, increasing prevalence of chronic & infectious diseases, and growing acceptance of smart devices. In addition, evolving applications of lateral flow assays and rising demand for lateral flow assays in the food & beverage industry offer significant growth opportunities for players operating in the lateral flow assays market. On the other hand, the reluctance towards changing existing diagnostic practices and the development of multiplexing assays are some of the factors challenging the growth of this market to a certain extent. Also, variance in lateral flow assay test results and stringent regulations are expected to hinder the growth of this market.
Based on product, the kits & reagents segment accounted for the largest share of the overall lateral flow assays market in 2020, led by the higher adoption rate of kits & reagents, increasing use of home-based lateral flow assay devices, and growing demand for point-of-care testing. On the basis of technique, the sandwich assays segment accounted for the largest share of the overall lateral flow assays market in 2020, due to the wide application of sandwich assays in various medical testing settings and their advantages, such as higher sensitivity and specificity for larger analytes.
Based on application, the clinical testing segment accounted for the largest share of the overall lateral flow assays market in 2020, on the back of increasing healthcare expenditure, rising initiatives towards health awareness, growing awareness about clinical testing, and increasing spread of various chronic and infectious diseases. Based on end user, diagnostic laboratories accounted for the largest share of the overall lateral flow assays market in 2020, on account of increasing adoption of lateral flow assays due to their benefits over conventional laboratory tests, increasing use of PoC tests, growing hospital admissions, and rapid growth in demand for lateral flow tests during COVID-19. Geographically, North America accounted for the largest share of the global lateral flow assays market in 2020, followed by Europe and Asia-Pacific. The increasing prevalence of chronic and infectious diseases, rising geriatric population, growing demand for point-of-care testing facilities, and presence of key players in the region are driving the growth of the North American lateral flow assays market.
Related Links:
Meticulous Research
Latest Industry News
- Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
- Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
- New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
- Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
- Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration
- Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows
- Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’
- Research Collaboration to Advance AI-Enhanced, Real-Time Optical Imaging in Lung Cancer Biopsy
- CACLP 2025 Unites Global Innovators in IVD Industry
- Bio-Rad to Acquire Digital PCR Developer Stilla Technologies
- ABL Signs Know-How License and Transfer Agreement for Siemens’ Fast Track Diagnostics PCR Portfolio
- Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
- New Partnership Revolutionizes Analyses of Biological Samples
- Medlab Middle East Looks to The Future of Laboratories
- Medix Biochemica Acquires German Immunoassay Solutions Developer Candor Bioscience
- bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more